These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 18339509)

  • 1. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases.
    Conejo MC; Hernández JR; Pascual A
    Diagn Microbiol Infect Dis; 2008 Jul; 61(3):343-5. PubMed ID: 18339509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
    Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
    Pai H; Seo MR; Choi TY
    Antimicrob Agents Chemother; 2007 Jan; 51(1):366-8. PubMed ID: 17074790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss.
    Lee K; Yong D; Choi YS; Yum JH; Kim JM; Woodford N; Livermore DM; Chong Y
    Int J Antimicrob Agents; 2007 Feb; 29(2):201-6. PubMed ID: 17204406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to extended-spectrum beta-lactams by the emergence of SHV-12 and the loss of OmpK35 in Klebsiella pneumoniae and Escherichia coli in Malaysia.
    Palasubramaniam S; Muniandy S; Navaratnam P
    J Microbiol Immunol Infect; 2009 Apr; 42(2):129-33. PubMed ID: 19597644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
    Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
    J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
    Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
    J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo selection of imipenem-resistant Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-15 and plasmid-encoded DHA-1 cephalosporinase.
    Cuzon G; Naas T; Guibert M; Nordmann P
    Int J Antimicrob Agents; 2010 Mar; 35(3):265-8. PubMed ID: 20034767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of OmpK35, OmpK36 Porins, and Production of β-Lactamases on Imipenem Susceptibility in Klebsiella pneumoniae Clinical Isolates, Cairo, Egypt.
    Wassef M; Abdelhaleim M; AbdulRahman E; Ghaith D
    Microb Drug Resist; 2015 Dec; 21(6):577-80. PubMed ID: 25945596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of tigecycline against enterobacteria producing two or more extended-spectrum beta-lactamases.
    Vázquez MF; Romero ED; García MI; Rodríguez JA; Bellido JL
    Int J Antimicrob Agents; 2008 Dec; 32(6):541-3. PubMed ID: 18789848
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 beta-Lactamase.
    Pichardo C; Rodríguez-Martínez JM; Pachón-Ibañez ME; Conejo C; Ibáñez-Martínez J; Martínez-Martínez L; Pachón J; Pascual A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3311-6. PubMed ID: 16048941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transconjugation and genotyping of the plasmid-mediated AmpC beta-lactamase and extended-spectrum beta-lactamase genes in Klebsiella pneumoniae.
    Shi WF; Zhou J; Qin JP
    Chin Med J (Engl); 2009 May; 122(9):1092-6. PubMed ID: 19493446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo transfer of plasmid-encoded ACC-1 AmpC from Klebsiella pneumoniae to Escherichia coli in an infant and selection of impermeability to imipenem in K. pneumoniae.
    Bidet P; Burghoffer B; Gautier V; Brahimi N; Mariani-Kurkdjian P; El-Ghoneimi A; Bingen E; Arlet G
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3562-5. PubMed ID: 16048985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
    Tan TY; Ng SY; Teo L; Koh Y; Teok CH
    J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.